For Panobinostat, a pan-HDAC inhibitor that has been hypothesized to act on cancer cells through a number of diverse mechanisms, we identified the up-regulation of STAT-1/interferon signaling as a principal factor of inherent resistance across multiple cancer lineages. The gene discussed is STAT1; the disease is cancer.